You are here: Industry Insights > Evusheld

News List

AstraZeneca welcomes US government’s announcement to purchase additional 500,000 doses of Evusheld ExpressPharma
January 14, 2022
Evusheld has Emergency Use Authorisation (EUA) for pre-exposure prophylaxis (prevention) of COVID-19.
Evusheld to prevent Covid-19: There won't be nearly enough for Americans who are eligible FirstWordPharma
December 27, 2021
The US government has only contracted for enough doses of AstraZeneca's Evusheld to cover less than one-tenth the number of people who are eligible for it, reported CNN.
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study WorldPharmaNews
December 20, 2021
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralising activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
Evusheld Long-Acting Antibody Combination Retains Neutralizing Activity Against Omicron Variant in Independent FDA Study AmericanPharmaceuticalReview
December 17, 2021
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
FDA Issues Emergency Use Authorization for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab), the First Antibody Therapy Authorized in the U.S. for Pre-Exposure Prophylaxis of COVID-19 prnewswire
December 13, 2021
Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab...
Evusheld (Formerly AZD7442) Long-Acting Antibody Combination Authorized For Emergency Use In The US For Prevention of COVID-19 AmericanPharmaceuticalReview
December 10, 2021
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected...